(Q43038083)

English

Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.

scientific article published on 25 June 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

interferon alfa

1 reference

based on heuristic

inferred from title

pegylated interferon

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

author name string

S K Tohra

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

S Taneja

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

S Ghosh

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

B K Sharma

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

A Duseja

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

R K Dhiman

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

A Das

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Y K Chawla

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

25 June 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Digestive Diseases and Sciences

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

2449-2455

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

A potential hidden source of hepatitis C infection among noninjecting drug users

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Infection with hepatitis C virus genotype 3--experience of a tertiary health care centre in south India

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Similar treatment response to peginterferon and ribavirin in Asian and Caucasian patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Peginterferon alfa-2a in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Sustained virological response in a predominantly hepatitis C virus genotype 4 infected population

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Sustained virological response based on rapid virological response in genotype-3 chronic hepatitis C treated with standard interferon in the Pakistani population

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Pegylated interferon plus optimized weight-based ribavirin dosing negate the influence of weight and body mass index on early viral kinetics and sustained virological response in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Hepatitis C virus and alcohol

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Impact of alcohol on hepatitis C virus replication and interferon signaling

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS10620-011-1770-3

21 January 2018

Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hepatitis C and alcohol

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased serum hepatitis C virus RNA levels among alcoholic patients with chronic hepatitis C.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Management of HCV infection: current issues and future options

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21706207

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10620-011-1770-3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43038083&oldid=2205761684"